Single-Cell and Multi-Omics-Based Characterization of Gastric Cancer Identifies TPP1 as a Potential Target for Gastric Cancer Progression and Treatment
Oncology Research · 2026
DOI: 10.32604/or.2026.070208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Yingying Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cancer-Associated Fibroblasts, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Serine Proteases. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.
- Department of Gastroenterology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China.
Zitieren
APA
Zhao, Y., Ma, J., Huang, R., & Pan, S. (2026). Single-Cell and Multi-Omics-Based Characterization of Gastric Cancer Identifies TPP1 as a Potential Target for Gastric Cancer Progression and Treatment. Oncology Research. https://doi.org/10.32604/or.2026.070208
Vancouver
Zhao Y, Ma J, Huang R, Pan S. Single-Cell and Multi-Omics-Based Characterization of Gastric Cancer Identifies TPP1 as a Potential Target for Gastric Cancer Progression and Treatment. Oncology Research. 2026. doi:10.32604/or.2026.070208
BibTeX
@article{Zhao2026,
author = {Zhao, Yingying and Ma, Jiakang and Huang, Rujin and Pan, Shuxian},
title = {Single-Cell and Multi-Omics-Based Characterization of Gastric Cancer Identifies TPP1 as a Potential Target for Gastric Cancer Progression and Treatment},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.070208}
}
EUVIMED